• Other
  • Exited

Radius Health, Inc. (NASDAQ: RDUS) is a science-driven biopharmaceutical company focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company’s lead product candidate, abaloparatide (BA058), is in development, in both injection (Abaloparatide-SC) and transdermal (Abaloparatide-TD) methods of administration, for the prevention of fractures in post-menopausal women at risk of fracture from osteoporosis.

radiuspharm.com